# Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk

Study · id `cardio:ct-nct05487950` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05487950](<https://clinicaltrials.gov/study/NCT05487950>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05487950

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 550 participants.

## Technical summary

Registry record NCT05487950. Randomized; no masking; primary purpose treatment. Start 2023-04-05 (anticipated); primary completion 2027-04-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 550 participants (planned count; ClinicalTrials.gov record NCT05487950, source copy `cardio:ctgov-nct05487950-2023-03-28`, retrieved 2026-10-26)
- Planned start: 2023-04-05 (anticipated) (ClinicalTrials.gov record NCT05487950, source copy `cardio:ctgov-nct05487950-2023-03-28`, retrieved 2026-10-26)
- Primary completion: 2027-04-05 (anticipated) (ClinicalTrials.gov record NCT05487950, source copy `cardio:ctgov-nct05487950-2023-03-28`, retrieved 2026-10-26)
- Completion: 2027-04-05 (anticipated) (ClinicalTrials.gov record NCT05487950, source copy `cardio:ctgov-nct05487950-2023-03-28`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05487950-2023-03-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Rivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk
- Acronym: SHORT RUN AF
- Condition: Excessive Supraventricular Ectopies or Short Atrial Runs (ESVEA)
- Intervention (Drug): Rivaroxaban group
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)

## Provenance

Content hash: 8018cfa33990b7a06de3fbf5ba2db0a8f6d19016b159b10670d65e3d0c6b4c3c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
